Amphotericin B

also known as Liposomal Amphotericin B · AmBisome · LAmB · AMB · ABLC · amphotericin B liposomal · Amphotericin B-deoxycholate · CAMB · +10 more

Developed for: visceral leishmaniasis · Cryptococcal meningitis · fungal infectious disease · HIV infectious disease · invasive aspergillosis · acute myeloid leukemia · aspergillosis · cutaneous leishmaniasis
+32 more
· neutropenia · histoplasmosis · allergic bronchopulmonary aspergillosis · blastomycosis · cancer · candidemia · candidiasis · chronic rhinosinusitis · fungal lung infectious disease · myelodysplastic syndrome · penicilliosis · vulvovaginal candidiasis · candidiasis, invasive · chronic mucocutaneous candidiasis · colorectal cancer · cryptococcosis · esophageal candidiasis · hematopoietic and lymphoid system neoplasm · Histoplasma capsulatum infectious disease · infectious disease · infectious disease with sepsis · leishmaniasis · mucocutaneous leishmaniasis · mycotic corneal ulcer · neoplasm · oral candidiasis · Zygomycosis · acute leukemia · bacterial vaginosis · dermatophytosis of scalp or beard · osteomyelitis · tinea unguium
Investigated by: Gilead Sciences · National Institute of Allergy and Infectious Diseases (NIAID) · Drugs for Neglected Diseases · Pfizer · Banaras Hindu University · Matinas BioPharma Nanotechnologies, Inc.
+100 more
· Enzon Pharmaceuticals, Inc. · Assistance Publique - Hôpitaux de Paris · Post Graduate Institute of Medical Education and Research, Chandigarh · Radboud University Medical Center · Rajendra Memorial Research Institute of Medical Sciences · University of Minnesota · University of Pittsburgh · Addis Ababa University · Astellas Pharma Inc · Bristol-Myers Squibb · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Federal University of Health Science of Porto Alegre · M.D. Anderson Cancer Center · Medecins Sans Frontieres, Netherlands · Merck Sharp & Dohme LLC · Ministry of Health, Brazil · Poitiers University Hospital · Shanghai Public Health Clinical Center · University of Brasilia · ABF Foundation for Medical Research · Accentia Biopharmaceuticals · Alessandro Pasqualotto · Alkermes, Inc. · Aravind Eye Hospitals, India · Aronex Pharmaceuticals · Astellas Pharma US, Inc. · Bach Mai Hospital · Bayside Health · Bill McGhee · CRB SAT APHP.SU Saint-Antoine hospital · CSPC Ouyi Pharmaceutical Co., Ltd. · Capital Medical University · Centro Nacional de Enfermedades Tropicales CENETROP · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Cornea Research Foundation of America · Dongkook Pharmaceutical Co., Ltd. · Dr. Frank Arguello Cancer Clinic · Duke University · Dutch Digestive Diseases Foundation · Erasmus Medical Center · European Organisation for Research and Treatment of Cancer - EORTC · Financiadora de Estudos e Projetos · First Affiliated Hospital of Guangxi Medical University · Fovea · Fundacion Nacional de Dermatologia · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Fundació Sant Joan de Déu · Guangxi Medical University · Guilin Medical College · H. Jaap Bonjer, PhD · Hospital Dermatológico de Jorochito · Hospital Nossa Senhora da Conceicao · Hospital Universitário Professor Edgard Santos · Hospital de Clinicas de Porto Alegre · Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam · Hui Bu · INSERMUMR938 · Immuno-mycologics, Inc. (IMMY) · Institute of Tropical Medicine, Belgium · Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com · Irmandade Santa Casa de Misericórdia de Porto Alegre · Janssen, LP · Liposome · London School of Hygiene and Tropical Medicine · Makerere University · Medstar Health Research Institute · Memorial Sloan Kettering Cancer Center · Ministry of Health, Spain · Nanfang Hospital, Southern Medical University · Nanning Second People's Hospital · National Cancer Institute (NCI) · National Hospital for Tropical Diseases, Hanoi, Vietnam · Nexstar Pharmaceuticals · PATH · all 106 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed invasive scopulariopsis infection 1 milestone
Filed	US (FDA)	—	invasive scopulariopsis infection	—	“Amphotericin B liposome for injection Nanodrug Anti-infective, nonspecific drug Invasive fungal infection Application for marketing approval submitted (US)” irasia.com ↗ “In November 2023, the Abbreviated New Drug Application (ANDA) for Amphotericin B Liposome for Injection was filed successfully with the US FDA.” irasia.com ↗
Approved Indication not stated 3 milestones
Label expansions (2)	US (FDA)	AMBISOME	—	2000-01-28 – 2000-06-16	fda.gov ↗
Label expansion	US (FDA)	ABELCET	—	1996-10-18	fda.gov ↗
Approved	US (FDA)	FUNGIZONE	—	1964-11-12	fda.gov ↗

Trials 107 · started per year

today

US approved 1964

1963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials · 1 met primary
Phase 1	NCT07530263	May 2026 → May 2027 expected	aspergillosis	Radboud University Medical Center	Not yet recruiting	No outcome recorded
Phase 1	NCT05749380	Sep 2020 → Jan 2022	fungal infectious disease, neutropenia	Dongkook Pharmaceutical Co., Ltd.	Completed	Met primary
Phase 1	NCT04267497	Oct 2019 → Nov 2022	invasive aspergillosis	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Completed	No outcome recorded
Phase 1	NCT03577509	Jul → Sep 2018	fungal infectious disease	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT00002316	—	Cryptococcal meningitis, HIV infectious disease	Alkermes, Inc.	Completed	No outcome recorded
Phase 1/23 trials · 1 met primary
Phase 1/2	NCT04031833	Oct 2019 → Nov 2022	Cryptococcal meningitis	Matinas BioPharma Nanotechnologies, Inc.	Completed	Met primary
Phase 1/2	NCT01845727	Feb 2014 → May 2016	cutaneous leishmaniasis	Drugs for Neglected Diseases	Completed	No outcome recorded
Phase 1/2	NCT01437020	—	immunotherapy induced hypophysitis, visceral leishmaniasis	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 231 trials · 1 met primary · 2 missed
Phase 2	NCT07300553	Jan → Nov 2026 expected	Crohn disease, ulcerative colitis	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 2	NCT05468372	Jul 2022 → Feb 2026	fungal lung infectious disease	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT04502381	Jul 2020 → Oct 2021	fungal lung infectious disease	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT04059770	Feb 2020 → Dec 2021	AIDS, histoplasmosis	Alessandro Pasqualotto	Completed	No outcome recorded
Phase 2	NCT03167957	Dec 2019 → Dec 2020	vulvovaginal candidiasis	Matinas BioPharma Nanotechnologies, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT03187691	Aug 2019 → Dec 2020	acute lymphoblastic leukemia, acute myeloid leukemia	Matinas BioPharma Nanotechnologies, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT03935828	Jun 2019 → Dec 2020	chronic rhinosinusitis, poisoning	United States Naval Medical Center, San Diego	Withdrawn	No outcome recorded
Phase 2	NCT03399955	May 2018 → May 2021	cutaneous leishmaniasis	Drugs for Neglected Diseases	Unknown	No outcome recorded
Phase 2	NCT03327727	Feb 2018 → Jan 2019	invasive aspergillosis	Vical	Terminated	No outcome recorded Stop: Business
Phase 2	NCT02656797	Jan 2018 → Jun 2021	cutaneous leishmaniasis	Soroka University Medical Center	Completed	No outcome recorded
Phase 2	NCT02971007	Nov 2016 → May 2017	vulvovaginal candidiasis	Matinas BioPharma Nanotechnologies, Inc.	Completed	No outcome recorded
Phase 2	NCT02629419	Sep 2016 → Nov 2021	chronic mucocutaneous candidiasis	Matinas BioPharma Nanotechnologies, Inc.	Completed	Met primary
Phase 2	NCT02273661	Nov 2014 → Jun 2019	allergic bronchopulmonary aspergillosis	Poitiers University Hospital	Completed	Missed primary
Phase 2	NCT01254708	Jan 2012 → Jan 2014	—	University Health Network, Toronto	Suspended	No outcome recorded Stop: Business
Phase 2	NCT01501708	Dec 2011 → Jun 2017	disease related to hematopoietic stem cell transplant, leukemia	Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT01615809	Oct 2011 → Jul 2013	acute myeloid leukemia, invasive aspergillosis, precursor lymphoblastic lymphoma/leukemia	Fundació Sant Joan de Déu	Completed	No outcome recorded
Phase 2	NCT02366884	Jul 2011 → Dec 2022	neoplasm	Dr. Frank Arguello Cancer Clinic	Unknown	No outcome recorded
Phase 2	NCT01067443	Mar 2010 → Jun 2011	visceral leishmaniasis	Drugs for Neglected Diseases	Completed	No outcome recorded
Phase 2	NCT00832208	Apr 2009 → Sep 2010	visceral leishmaniasis	Drugs for Neglected Diseases	Terminated	Missed primary
Phase 2	NCT00371995	Oct 2007 → Aug 2009	visceral leishmaniasis	Banaras Hindu University	Completed	No outcome recorded
Phase 2	NCT00467883	Jun 2007 → Jun 2011	Zygomycosis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00451711	May 2007 → Oct 2014	acute myeloid leukemia	Bayside Health	Unknown	No outcome recorded
Phase 2	NCT00497601	Feb 2007 → Jul 2008	visceral leishmaniasis	Banaras Hindu University	Completed	No outcome recorded
Phase 2	NCT00418951	Nov 2006 → Oct 2009	acute myeloid leukemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00370825	Sep 2006 → ?	visceral leishmaniasis	Banaras Hindu University	Completed	No outcome recorded
Phase 2	NCT00326157	Jun 2006 → Jan 2009	fungal infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00145249	May 2005 → Apr 2008	Cryptococcal meningitis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00148148	May 2004 → Dec 2007	disease related to hematopoietic stem cell transplant, fungal infectious disease	University Hospital Muenster	Completed	No outcome recorded
Phase 2	NCT00082537	Apr 2004 → Oct 2006	neutropenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00047827	Dec 2002 → Feb 2003	invasive aspergillosis	Astellas Pharma Inc	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00001065	? → Apr 1998	HIV infectious disease, oral candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/34 trials · 1 missed
Phase 2/3	NCT04018417	Jul 2019	Fuchs' endothelial dystrophy	Cornea Research Foundation of America	Withdrawn	No outcome recorded
Phase 2/3	NCT03945448	Jun 2019 → Jun 2027 expected	Cryptococcal meningitis	Makerere University	Recruiting	Missed primary
Phase 2/3	NCT01857479	May 2013 → Jun 2015	allergic bronchopulmonary aspergillosis	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT00263315	Jan 2000 → May 2006	aspergillosis	Erasmus Medical Center	Completed	No outcome recorded
Phase 331 trials · 4 met primary · 2 missed
Phase 3	NCT07261150	Nov 2026 → Dec 2030 expected	histoplasmosis	University of Minnesota	Not yet recruiting	No outcome recorded
Phase 3	NCT06525389	Nov 2026 → Sep 2030 expected	penicilliosis	Duke University	Not yet recruiting	No outcome recorded
Phase 3	NCT05814432	Jan 2025 → Aug 2026 overdue	AIDS, Histoplasma capsulatum infectious disease	Federal University of Health Science of Porto Alegre	Recruiting	Missed primary
Phase 3	NCT05865743	Oct 2024 → Dec 2027 expected	carcinoma of esophagus	Radboud University Medical Center	Recruiting	No outcome recorded
Phase 3	NCT05707832	Mar 2023 → Jul 2024	candidiasis, invasive, invasive aspergillosis	CSPC Ouyi Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT05108545	Dec 2021 → Jul 2022	neutropenia	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04799236	Apr 2021 → Apr 2024	mucocutaneous leishmaniasis	Fundacion Nacional de Dermatologia	Unknown	No outcome recorded
Phase 3	NCT04140461	Jan 2020 → Mar 2022	Cryptococcal meningitis, HIV infectious disease	Shanghai Public Health Clinical Center	Unknown	No outcome recorded
Phase 3	NCT03656081	Dec 2018 → Jun 2027 expected	aspergillosis	Poitiers University Hospital	Recruiting	No outcome recorded
Phase 3	NCT02570321	Nov 2015 → Jun 2018	mycotic corneal ulcer	University of California, San Francisco	Completed	Missed primary
Phase 3	NCT02011958	Jul 2014 → Aug 2016	visceral leishmaniasis	Drugs for Neglected Diseases	Completed	No outcome recorded
Phase 3	NCT01259713	Apr 2011 → Dec 2013	fungal infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02025491	Apr 2011 → Feb 2013	leishmaniasis	Hospital Universitário Professor Edgard Santos	Completed	No outcome recorded
Phase 3	NCT00750737	Jun 2008 → Jun 2012	fungal infectious disease, hematopoietic and lymphoid system neoplasm	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00696969	Jun 2008 → Jan 2010	visceral leishmaniasis	Drugs for Neglected Diseases	Completed	Met primary
Phase 3	NCT00628719	Feb → Aug 2008	visceral leishmaniasis	Banaras Hindu University	Completed	Met primary
Phase 3	NCT00523965	Sep 2007 → Aug 2009	visceral leishmaniasis	Banaras Hindu University	Completed	No outcome recorded
Phase 3	NCT00425620	Dec 2006 → Oct 2007	chronic rhinosinusitis	Accentia Biopharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00177710	Jan 2006 → Dec 2007	fungal infectious disease	University of Pittsburgh	Completed	No outcome recorded
Phase 3	NCT00235651	Oct 2005 → Apr 2006	lung disorder	University of Pittsburgh	Terminated	No outcome recorded
Phase 3	NCT00177684	Sep 2004 → Sep 2005	fungal infectious disease	University of Pittsburgh	Completed	No outcome recorded
Phase 3	NCT00216346	Jun 2003 → Nov 2004	visceral leishmaniasis	PATH	Completed	Met primary
Phase 3	NCT00158730	Apr 2003 → Jan 2005	invasive aspergillosis	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00008359	Aug 2000 → Mar 2003	cancer	Memorial Sloan Kettering Cancer Center	Completed	Met primary
Phase 3	NCT00003938	Jun 1999 → May 2003	cancer	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 3	NCT00163111	Sep 1998 → May 2003	candidemia	Pfizer	Completed	No outcome recorded
Phase 3	NCT00001646	Aug 1997 → Aug 2000	AIDS, aspergillosis, neutropenia	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002742	Jan 1996 → Sep 2007	infectious disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +1	Aronex Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00002159	—	HIV infectious disease, blastomycosis, histoplasmosis	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00002277	—	HIV infectious disease, fungal infectious disease	Pfizer	Completed	No outcome recorded
Phase 3	NCT00001017	? → Jul 1991	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded

Phase 420 trials · 2 missed
Phase 4	NCT06376201	Apr 2024 → Feb 2025	fungal infectious disease	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT02320604	Mar → Nov 2018	morbid obesity	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT02686853	Jan 2016 → Jan 2018	Cryptococcal meningitis	Hui Bu	Unknown	No outcome recorded
Phase 4	NCT02283905	Jun 2015 → Sep 2020	blastomycosis	University of Manitoba	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01566552	Jun 2014 → Dec 2016	visceral leishmaniasis	Banaras Hindu University	Unknown	No outcome recorded
Phase 4	NCT03311607	Apr 2014 → Oct 2015	cutaneous leishmaniasis	Medecins Sans Frontieres, Netherlands	Completed	No outcome recorded
Phase 4	NCT01740947	Jan 2013 → Mar 2017	colorectal cancer	H. Jaap Bonjer, PhD	Terminated	Missed primary
Phase 4	NCT01310738	Feb 2011 → Oct 2014	visceral leishmaniasis	University of Brasilia	Terminated	Missed primary
Phase 4	NCT00986713	Jun 2008 → Sep 2010	invasive aspergillosis	Capital Medical University	Unknown	No outcome recorded
Phase 4	NCT00697944	Mar 2008 → Feb 2009	candidiasis, infectious disease with sepsis	Fovea	Unknown	No outcome recorded
Phase 4	NCT01032187	Oct 2007 → Jan 2010	visceral leishmaniasis	University of Brasilia	Completed	No outcome recorded
Phase 4	NCT00670657	May 2007 → Dec 2008	candidemia	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT01656382	Jan 2007 → Jan 2010	cryptococcosis	Medstar Health Research Institute	Withdrawn	No outcome recorded
Phase 4	NCT00386997	Nov 2006 → Sep 2007	fungal infectious disease	Gilead Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00936910	Sep 2006 → Aug 2010	fungal infectious disease	Bill McGhee	Completed	No outcome recorded
Phase 4	NCT00161356	Sep 2005 → Dec 2007	—	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT00334412	Mar 2004 → May 2006	invasive aspergillosis	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00362544	Oct 2003 → Mar 2006	leukemia	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00190463	Apr 2003 → Jul 2006	chemotherapy-induced toxicity, hematopoietic and lymphoid cell neoplasm	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 4	NCT00001107	? → Nov 2005	candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase not applicable13 trials · 1 met primary
—	NCT07559032	Apr 2026 → Dec 2028 expected	fungal infectious disease	Peking University People's Hospital	Not yet recruiting	No outcome recorded
—	NCT07337720	Dec 2025 → Dec 2026 expected	invasive aspergillosis	Southeast University, China	Not yet recruiting	No outcome recorded
—	NCT06926569	May 2025 → Jan 2026 overdue	fungal infectious disease	Shanghai Public Health Clinical Center	Not yet recruiting	No outcome recorded
—	NCT03827278	Dec 2018 → Dec 2021	penicilliosis	Guangxi Medical University	Unknown	Met primary
—	NCT00310505	Jan 2003 → ?	visceral leishmaniasis	Banaras Hindu University	Completed	No outcome recorded
—	NCT00002068	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00000708	? → Jul 1991	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000639	? → Sep 1997	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002074	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002019	—	Cryptococcal meningitis, HIV infectious disease	Liposome	Completed	No outcome recorded
—	NCT00002075	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002305	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002041	—	HIV infectious disease, esophageal candidiasis	Bristol-Myers Squibb	Completed	No outcome recorded

Comparator or background therapy34 trials
Phase 1	NCT06616168 Background	Sep 2023 → Aug 2026 overdue	bacterial vaginosis	Danylo Halytsky Lviv National Medical University	Active not recruiting	No outcome recorded
Phase 1/2	NCT06449040 Comparator	Mar 2019 → Sep 2021	cutaneous leishmaniasis	Hospital Universitário Professor Edgard Santos	Completed	No outcome recorded
Phase 1/2	NCT00885703 Comparator	Apr 2010 → Jan 2017	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT05593666 Comparator	Dec 2022 → Apr 2025	visceral leishmaniasis	Drugs for Neglected Diseases	Completed	No outcome recorded
Phase 2	NCT03112031 Background	Oct 2017 → Jul 2018	HIV infectious disease, meningoencephalitis, streptococcal meningitis	Oxford University Clinical Research Unit, Vietnam	Completed	Missed primary
Phase 2	NCT00419770 Background	Oct 2007 → Dec 2009	Zygomycosis	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Completed	No outcome recorded
Phase 2	NCT00847678 Background	Aug 2006 → Nov 2007	Cryptococcal meningitis	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00076869 Background	Jan 2003 → Sep 2004	invasive aspergillosis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00012467 Background	Jan 2000 → Jul 2001	Cryptococcal meningitis, HIV infectious disease	InterMune	Completed	No outcome recorded
Phase 2	NCT00000776 Background	? → Sep 1996	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2/3	NCT06666322 Comparator	May 2025 → Apr 2032 expected	Cryptococcal meningitis, HIV infectious disease	University of Minnesota	Recruiting	No outcome recorded
Phase 2/3	NCT06980493 Comparator	Apr → Jun 2025 overdue	dermatophytosis of scalp or beard	Sohag University	Active not recruiting	No outcome recorded
Phase 2/3	NCT06040489 Comparator	Jun 2022 → Jun 2024	mucocutaneous leishmaniasis	University of Brasilia	Unknown	No outcome recorded
Phase 3	NCT07463040 Comparator	Jan 2027 → Mar 2029 expected	cutaneous leishmaniasis	Institute of Tropical Medicine, Belgium	Not yet recruiting	No outcome recorded
Phase 3	NCT05541107 Comparator	Jan 2023 → Oct 2024	Cryptococcal meningitis	Matinas BioPharma Nanotechnologies, Inc.	Unknown	No outcome recorded
Phase 3	NCT05101187 Comparator	Apr 2022 → Nov 2025	invasive aspergillosis	F2G Ltd	Completed	No outcome recorded
Phase 3	NCT01122771 Comparator	May 2010 → Mar 2014	visceral leishmaniasis	Drugs for Neglected Diseases	Completed	Met primary
Phase 3	NCT01293643 Comparator	May 2010 → Jan 2011	bacterial vaginosis, vulvovaginal candidiasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01058174 Comparator	Dec 2009 → May 2012	fungal infectious disease	Astellas Pharma Inc	Completed	Met primary
Phase 3	NCT00889356 Comparator	Sep 2009 → Mar 2010	bacterial vaginosis, candidiasis	Zodiac Produtos Farmaceuticos S.A.	Unknown	No outcome recorded
Phase 3	NCT00876824 Comparator	Jul 2009 → Jan 2011	visceral leishmaniasis	Bharat Serums and Vaccines Limited	Completed	No outcome recorded
Phase 3	NCT00624143 Comparator	Feb 2008 → Dec 2009	acute leukemia	All India Institute of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT00106288 Comparator	Jan 2003 → Dec 2005	candidiasis	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00003315 Background	Jul → Dec 1997	infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 4	NCT07072923 Comparator	Sep 2025 → Jul 2027 expected	osteomyelitis	University of Arizona	Not yet recruiting	No outcome recorded
Phase 4	NCT06756191 Comparator	Jan → Jul 2025 overdue	fungal lung infectious disease	Bin Cao	Not yet recruiting	No outcome recorded
Phase 4	NCT06178627 Comparator	Aug 2023 → Aug 2025 overdue	Cryptococcal meningitis	Huashan Hospital	Enrolling by invitation	No outcome recorded
Phase 4	NCT06413056 Comparator	Oct 2022 → May 2023	candidiasis, invasive	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT03814343 Comparator	Jan 2019 → Nov 2020	tinea unguium	Mahidol University	Completed	No outcome recorded
Phase 4	NCT01303549 Comparator	Nov 2011 → May 2014	fungal infectious disease, liver disorder	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT00634166 Background	Sep 2007 → Dec 2013	—	Mylan Inc.	Terminated	No outcome recorded
Phase 4	NCT00421187 Comparator	Mar 2007 → Apr 2008	neutropenia	Gilead Sciences	Terminated	No outcome recorded Stop: Enrollment
—	NCT02088970 Background	Sep 2014 → Apr 2017	fungal keratitis	Nantes University Hospital	Terminated	No outcome recorded
—	NCT02136030 Comparator	Feb 2011 → Dec 2015	Cryptococcal meningitis	TTY Biopharm	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 31

Date	Issuer	Release
2026-06-18	Shionogi	Results F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis shionogi.com ↗ The study met its primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% vs. 24.3% for AmBisome® followed by SOC (difference of -0.5% with 95% confidence interval of -13.1 to 10.8%).
2026-06-18	F2G Ltd	Results F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis f2g.com ↗ The study met its primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% vs. 24.3% for AmBisome® followed by SOC (difference of -0.5% with 95% confidence interval of -13.1 to 10.8%).
2026-04-29	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION FOR INFUSION (HC1507G2) APPROVED IN EUROPE irasia.com ↗
2025-03-03	TLC Biopharmaceuticals, Inc.	Regulatory TLC BioSciences Secures Marketing Approval for Ampholipad® in China tlcbio.com ↗ Following the approval of AmBisome in China in 2023, TLC demonstrated the quality and bioequivalence of Ampholipad to AmBisome within two years, obtaining NMPA approval.
2024-09-16	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ Amphotericin B Liposome for Injection (the ‘‘Product ’’) developed by the Group has obtained drug registration approval granted by the Nationa l Medical Products Administration of the People ’s Republic of China.
2024-07-17	Drugs for Neglected Diseases	Results Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease dndi.org ↗ This group had an 80% cure rate, with MF+LAmB proving to be a good treatment alternative.
2024-03-22	Matinas BioPharma Nanotechnologies, Inc.	Results Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response matinasbiopharma.com ↗ The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
2023-08-22	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases matinasbiopharma.com ↗ With six weeks of LNC-enabled oral amphotericin B, statistically fewer lab abnormalities occurred than with one week of intravenous amphotericin B.
2023-04-18	Matinas BioPharma Nanotechnologies, Inc.	Results Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID matinasbiopharma.com ↗ Following transition, MAT2203 was well-tolerated, and led to a robust clinical response with no renal adverse effects, allowing for six continuous months of treatment with regular outpatient monitoring.
2022-06-08	Drugs for Neglected Diseases	Results New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV dndi.org ↗ In Ethiopia, the new treatment strategy was shown to have an 88% efficacy rate at the end of therapy (after 58 days), whereas the efficacy of the current standard treatment was 55% in the trial.
2021-12-15	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection sunpharma.com ↗
2021-12-03	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - INCLUSION OF ANFULIKE IN THE NATIONAL REIMBURSEMENT DRUG LIST irasia.com ↗ The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “ Group”) is pleased to announce that Anfulike ® (“Amphotericin B Cholesteryl Sulfate Complex for Injection (50mg)”) (the “ Product”) of the Group has been included in the category B of the National Reimbursement Drug List (2021) (“ NRDL”).
2021-05-27	Halcygen Pharmaceuticals Limited	Regulatory TLC and Strides partner to launch Liposomal Amphotericin B in India strides.com ↗ TLC receives approval from Central Drugs Standard Control Organization of India to launch Amphotericin B Liposome for Injection 50mg
2021-04-01	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ “AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION” OBTAINS DRUG REGISTRATION APPROVAL
2020-08-20	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203 matinasbiopharma.com ↗ They concluded that MAT2203 was well tolerated when given in 4-6 divided daily doses without the toxicities commonly seen with IV amphotericin B.
2019-05-28	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio matinasbiopharma.com ↗ Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden
2019-01-16	Drugs for Neglected Diseases	Results Combination therapy found to be more effective in treating patients with leishmaniasis and HIV \| DNDi dndi.org ↗
2018-06-06	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform matinasbiopharma.com ↗ Data demonstrate safe, effective oral delivery of antimicrobial drugs utilizing LNC technology
2016-07-13	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016 matinasbiopharma.com ↗ Preclinical studies demonstrate comparable survival upon treatment with combination of oral encochleated amphotericin B plus flucytosine compared to injected amphotericin B
2015-09-18	Matinas BioPharma Nanotechnologies, Inc.	Results Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015 matinasbiopharma.com ↗ The results of the study show that in Candida- infected mice MAT2203 is taken up from the gastrointestinal (GI) tract resulting in significant concentrations of AmB in targeted tissues, but undetectable AmB levels in plasma.
2014-10-14	Drugs for Neglected Diseases	Results Study Results Support WHO Recommendations for Safe and Effective Kala-azar Treatments in Bangladesh \| DNDi dndi.org ↗ The combination treatments (AmBisome® + miltefosine; AmBisome® + paromomycin; paromomycin + miltefosine) were non-inferior to AmBisome® monotherapy: the combinations of AmBisome® + paromomycin and paromomycin + miltefosine demonstrated excellent cure rates of above 98%, thus comparable with AmBisome® monotherapy.
2011-01-24	Drugs for Neglected Diseases	Results Study shows the safety and efficacy of combination treatment for visceral leishmaniasis in India \| DNDi dndi.org ↗ A phase III clinical trial study published online in The Lancet shows that three short-course combination treatments for visceral leishmaniasis in India are efficacious and safe.
2009-06-19	Sumitomo Pharma America, Inc.	Regulatory Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection sumitomo-pharma.com ↗ Visceral leishmaniasis can be treated by AmBisome ® under the newly added indication, though the same has already been allowed outside of Japan.
2005-12-12	Gilead Sciences	Results Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections gilead.com ↗ In this study the overall rate of response for the two dosing regimens at end of treatment were associated with similar efficacy and survival (50 percent in the standard dosing group versus 46 percent in the high loading-dose group).
2000-11-17	Gilead Sciences	Results Study Results Published in Journal of Clinical Infectious Diseases Demonstrate That Ambisome® Has an Improved Safety Profile Compared to Abelcet® gilead.com ↗ Results of the study indicate that AmBisome demonstrates an improved safety profile in a direct comparison with Abelcet with regard to nephrotoxicity and infusion-related reactions.
2000-09-17	Gilead Sciences	Results Pharmacoeconomic Study Compares Total Hospital Costs of AmBisome® to Abelcet® for Empirical Treatment of Patients with Febrile Neutropenia gilead.com ↗ In this study, AmBisome 3mg/kg/day was found to be more cost-effective than Abelcet 5mg/kg/day due to a significant reduction in treatment-related nephrotoxicity.
2000-09-17	Gilead Sciences	Results Gilead Announces Data Demonstrating that Single Dose of AmBisome® Safely and Effectively Treats Visceral Leishmaniasis in India gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising results from a study conducted in India examining the use of a single dose of AmBisome® (amphotericin B) liposome for injection as a treatment for visceral leishmaniasis (VL).
2000-07-05	Gilead Sciences	Regulatory FDA Approves AmBisome® for the Treatment of Cryptococcal Meningitis in AIDS Patients gilead.com ↗ Fujisawa Healthcare, Inc. and Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved the antifungal drug AmBisome® [(amphotericin B) liposome for injection] for the treatment of cryptococcal meningitis in HIV-infected patients.
2000-03-20	Gilead Sciences	Regulatory Canada Approves Antifungal Agent Ambisome® gilead.com ↗ March 20, 2000 Fujisawa Healthcare, Inc. (Fujisawa) and Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Fujisawa Canada, Inc., a subsidiary of Fujisawa, received marketing approval from Health Canada for the anti-fungal agent AmBisome® (amphotericin B) liposome for injection.
2000-02-10	Gilead Sciences	Regulatory New AmBisome® Label Includes Claim Of Superior Safety Profile Compared To Abelcet® In Febrile Neutropenic Cancer Patients gilead.com ↗ Fujisawa Healthcare, Inc. and Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Food and Drug Administration (FDA) has approved a supplemental new drug application for AmBisome® (amphotericin B) liposome for injection.
1999-09-27	Gilead Sciences	Results AmBisome® Phase III Study For Cryptococcal Meningitis gilead.com ↗ The study results indicate that AmBisome is as effective as amphotericin B, yet appears to be significantly less toxic.

All press releases naming this drug 75 releases

Date	Issuer	Release
2026-07-13	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals matinasbiopharma.com ↗
2026-06-18	Shionogi	F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis shionogi.com ↗
2026-06-18	F2G Ltd	F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis f2g.com ↗
2026-04-29	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION FOR INFUSION (HC1507G2) APPROVED IN EUROPE irasia.com ↗
2025-03-03	TLC Biopharmaceuticals, Inc.	TLC BioSciences Secures Marketing Approval for Ampholipad® in China tlcbio.com ↗
2024-10-31	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction matinasbiopharma.com ↗
2024-09-16	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - AMPHOTERICIN B LIPOSOME FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
2024-07-17	Drugs for Neglected Diseases	Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease dndi.org ↗
2024-06-24	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program matinasbiopharma.com ↗
2024-06-13	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin matinasbiopharma.com ↗
2024-04-30	Matinas BioPharma Nanotechnologies, Inc.	In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy matinasbiopharma.com ↗
2024-03-22	Matinas BioPharma Nanotechnologies, Inc.	Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response matinasbiopharma.com ↗
2024-02-26	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution matinasbiopharma.com ↗
2024-02-20	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis matinasbiopharma.com ↗
2023-12-21	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA matinasbiopharma.com ↗
2023-10-11	Matinas BioPharma Nanotechnologies, Inc.	Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution matinasbiopharma.com ↗
2023-09-27	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek matinasbiopharma.com ↗
2023-08-22	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases matinasbiopharma.com ↗
2023-04-18	Matinas BioPharma Nanotechnologies, Inc.	Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID matinasbiopharma.com ↗
2023-03-02	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID matinasbiopharma.com ↗
2022-10-21	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% matinasbiopharma.com ↗
2022-10-19	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022 matinasbiopharma.com ↗
2022-10-12	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022 matinasbiopharma.com ↗
2022-07-25	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis matinasbiopharma.com ↗
2022-06-08	Drugs for Neglected Diseases	New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV dndi.org ↗
2021-12-16	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis matinasbiopharma.com ↗
2021-12-15	Sun Pharmaceutical Industries, Inc.	Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection sunpharma.com ↗
2021-12-03	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - INCLUSION OF ANFULIKE IN THE NATIONAL REIMBURSEMENT DRUG LIST irasia.com ↗
2021-09-13	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold matinasbiopharma.com ↗
2021-08-16	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections matinasbiopharma.com ↗
2021-05-27	Halcygen Pharmaceuticals Limited	TLC and Strides partner to launch Liposomal Amphotericin B in India strides.com ↗
2021-05-26	Zydus Lifesciences Limited	Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India zyduslife.com ↗
2021-04-01	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
2020-10-26	Knight Therapeutics (USA) Inc	Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil knighttx.com ↗
2020-10-19	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis matinasbiopharma.com ↗
2020-08-20	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203 matinasbiopharma.com ↗
2020-02-19	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis matinasbiopharma.com ↗
2019-10-14	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis matinasbiopharma.com ↗
2019-10-07	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis matinasbiopharma.com ↗
2019-07-25	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis matinasbiopharma.com ↗
2019-05-28	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio matinasbiopharma.com ↗
2019-01-16	Drugs for Neglected Diseases	Combination therapy found to be more effective in treating patients with leishmaniasis and HIV \| DNDi dndi.org ↗
2018-06-06	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform matinasbiopharma.com ↗
2018-04-19	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease matinasbiopharma.com ↗
2018-01-08	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis matinasbiopharma.com ↗
2017-08-08	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 matinasbiopharma.com ↗
2017-06-26	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis matinasbiopharma.com ↗
2017-06-03	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis matinasbiopharma.com ↗
2017-06-02	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis matinasbiopharma.com ↗
2017-05-30	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference matinasbiopharma.com ↗
2017-03-06	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis matinasbiopharma.com ↗
2016-11-21	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis matinasbiopharma.com ↗
2016-09-28	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203 matinasbiopharma.com ↗
2016-09-07	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA matinasbiopharma.com ↗
2016-07-13	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016 matinasbiopharma.com ↗
2016-02-08	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B matinasbiopharma.com ↗
2015-12-17	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA matinasbiopharma.com ↗
2015-10-05	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B – matinasbiopharma.com ↗
2015-09-18	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015 matinasbiopharma.com ↗
2015-08-18	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA matinasbiopharma.com ↗
2015-07-14	Matinas BioPharma Nanotechnologies, Inc.	Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015 matinasbiopharma.com ↗
2014-10-22	iCo Therapeutics Inc.	iCo Therapeutics Announces Advancement of Oral Amphotericin B Program icotherapeutics.com ↗
2014-10-14	Drugs for Neglected Diseases	Study Results Support WHO Recommendations for Safe and Effective Kala-azar Treatments in Bangladesh \| DNDi dndi.org ↗
2012-10-12	iCo Therapeutics Inc.	iCo Therapeutics’ Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position icotherapeutics.com ↗
2011-01-24	Drugs for Neglected Diseases	Study shows the safety and efficacy of combination treatment for visceral leishmaniasis in India \| DNDi dndi.org ↗
2009-06-19	Sumitomo Pharma America, Inc.	Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection sumitomo-pharma.com ↗
2008-11-18	iCo Therapeutics Inc.	iCo Therapeutics Oral Amphotericin B Poster at AAPS icotherapeutics.com ↗
2005-12-12	Gilead Sciences	Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections gilead.com ↗
2000-11-17	Gilead Sciences	Study Results Published in Journal of Clinical Infectious Diseases Demonstrate That Ambisome® Has an Improved Safety Profile Compared to Abelcet® gilead.com ↗
2000-09-17	Gilead Sciences	Pharmacoeconomic Study Compares Total Hospital Costs of AmBisome® to Abelcet® for Empirical Treatment of Patients with Febrile Neutropenia gilead.com ↗
2000-09-17	Gilead Sciences	Gilead Announces Data Demonstrating that Single Dose of AmBisome® Safely and Effectively Treats Visceral Leishmaniasis in India gilead.com ↗
2000-07-05	Gilead Sciences	FDA Approves AmBisome® for the Treatment of Cryptococcal Meningitis in AIDS Patients gilead.com ↗
2000-03-20	Gilead Sciences	Canada Approves Antifungal Agent Ambisome® gilead.com ↗
2000-02-10	Gilead Sciences	New AmBisome® Label Includes Claim Of Superior Safety Profile Compared To Abelcet® In Febrile Neutropenic Cancer Patients gilead.com ↗
1999-09-27	Gilead Sciences	AmBisome® Phase III Study For Cryptococcal Meningitis gilead.com ↗

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 147 sources stand behind the page.

Field	Value	Cited text
Known as	Amphotericin B	“Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin,...” NCT07072923 ↗ 101 “'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗ “Participants with human immunodeficiency virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with...” PMID 39044381 ↗ Feb 2025 “A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.” PMID 20431381 ↗ May 2010 “Preparation Prepare a 2.5% amphotericin B solution by reconstitute liposomal amphotericin B 50 mg vial in 20 ml distilled water result in a final concentration of 2.5 mg/ml.” NCT06980493 ↗ “The SDD treatment comprises two oral liquids: an oral suspension containing amphotericin B and an oral solution containing both colistin sulfate and tobramycin.” PMID 41345690 ↗ Dec 2025 “Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml” NCT03935828 ↗ “Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated” NCT04502381 ↗ “Amphotericin B colloidal dispersion (ABCD) is a less toxic formulation of amphotericin B for the treatment of invasive fungal infections.” PMID 34686365 ↗ Oct 2021 “Liposomal Amphotericin B (AmBisome ®) has been shown in animals to be concentrated in the liver, lungs and leukocytes.” NCT00161356 ↗ “Pharmacokinetics of Liposomal Amphotericin B (AmBisome®) Given Intravenously to Patients Undergoing Bariatric Surgery” NCT02320604 ↗ Show 91 more sources
Known as	Abelcet	“Pharmacokinetic and Deposition Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet®) in Lung Transplant Recipients (Radiotagging Protocol)” NCT00235651 ↗ 1 “Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)” NCT00177684 ↗
Known as	ABLC	“Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.” PMID 20881664 ↗ Dec 2010 3 “three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B)” NCT00002019 ↗ NCT00750737 ↗ NCT01656382 ↗
Known as	AMB	“To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis” NCT00000708 ↗ 4 “Historically, amphotericin B (AMB) has been considered the "gold standard" in antifungal treatments due to its broad spectrum of activity and lack of emergence of resistance.” NCT04031833 ↗ “There are no data comparing voriconazole versus amphotericin B (AmB) as AFP in either adult/pediatric AL.” PMID 22042283 ↗ Dec 2011 “intravenous amphotericin B deoxycholate (AmB) 0.7 mg/kg (the standard therapy)” PMID 19441980 ↗ Jun 2009 “Amphotericin B (AmB) is the corner stone in CM treatment.” NCT04140461 ↗
Known as	AmBD	“control group: amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines” NCT06926569 ↗
Known as	AmBisome	“The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.” NCT00177710 ↗ 26 “A liposomal formulation of amphotericin B, AmBisome, is also available, and is substantially less nephrotoxic than amphotericin B, but is expensive.” NCT00696969 ↗ “Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial” NCT00467883 ↗ “An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months” NCT02273661 ↗ “COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis” NCT00334412 ↗ “Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved” NCT06449040 ↗ “Liposomal amphotericin B (AmBisome) are approved drugs for visceral leishmaniasis.” NCT00371995 ↗ “Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo” NCT00263315 ↗ “Liposomal amphotericin B (AmBisome®) and sodium stibogluconate” NCT01067443 ↗ “Drug: Amphotericine in liposome (Ambisome®)” NCT06980493 ↗ “Amphotericine in liposome (Ambisome®)” NCT00697944 ↗ Show 16 more sources
Known as	AmBisome (liposomal amphotericin B)	“AmBisome® (liposomal amphotericin B)” NCT05101187 ↗
Known as	Amp-B	“Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited)” NCT04502381 ↗
Known as	Amphotericin B Lipid Complex	“three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B)” NCT00002019 ↗ 1 “Amphotericin B Lipid Complex (ABLC)” NCT00750737 ↗
Known as	amphotericin B liposomal	“Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks” NCT00467883 ↗ 2 “Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole” NCT02366884 ↗ NCT00936910 ↗
Known as	Amphotericin B-deoxycholate	“control group: amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines” NCT06926569 ↗ 2 “intravenous amphotericin B deoxycholate (AmB) 0.7 mg/kg (the standard therapy)” PMID 19441980 ↗ Jun 2009 “Drug: Amphotericin B-deoxycholate” NCT01032187 ↗
Known as	Amphotericine in liposome	“Drug: Amphotericine in liposome (Ambisome®)” NCT06980493 ↗ 1 “Amphotericine in liposome (Ambisome®)” NCT00697944 ↗
Known as	Amphotret	“Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited)” NCT04502381 ↗
Known as	CAMB	“Oral Encochleated Amphotericin B (CAMB/MAT2203)” NCT02971007 ↗ 2 “oral encochleated Amphotericin B (CAMB/MAT2203)” NCT03187691 ↗ “Oral Encochleated Amphotericin B (CAMB)” NCT03167957 ↗
Known as	Fungizone	“Amphotericin B (Fungizone®) Bottle 10% (4000mg/40ml) oral solution Dose 500mg x4 (20ml) daily orally” NCT07300553 ↗ 2 “compared to Fungizone (Amphotericin B)” NCT00002019 ↗ “= Fortum + vancomycin + Fungizone” NCT02088970 ↗
Known as	LAmB	“This is a prospective, open-label, multicenter, single-arm exploratory clinical study designed to evaluate the safety and effectiveness of liposomal amphotericin B (L-AmB) in...” NCT07337720 ↗ 6 “Liposomal amphotericin B (L-AmB) is the drug of choice for treatment, but access is restricted due to the high drug and hospitalization costs of the conventional long regimens.” PMID 37232940 ↗ Oct 2023 “Patients were scheduled to receive 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month and surgery was performed when appropriate.” PMID 26316385 ↗ Aug 2015 “Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.” PMID 28531175 ↗ May 2017 “single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine” PMID 18781879 ↗ Oct 2008 “Liposomal amphotericin B (L-AmB) is considered the therapy of choice for AIDS-associated histoplasmosis.” NCT04059770 ↗ “Liposomal Amphotericin B (LAmB)” NCT06525389 ↗
Known as	Liposomal Amphotericin B	“CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis...” NCT00670657 ↗ 27 “Liposomal amphotericin B (L-AmB) is the drug of choice for treatment, but access is restricted due to the high drug and hospitalization costs of the conventional long regimens.” PMID 37232940 ↗ Oct 2023 “Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.” PMID 28531175 ↗ May 2017 “Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial” NCT00467883 ↗ “Liposomal Amphotericin B (AmBisome ®) has been shown in animals to be concentrated in the liver, lungs and leukocytes.” NCT00161356 ↗ “An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months” NCT02273661 ↗ “Liposomal amphotericin B (L-AmB) is considered the therapy of choice for AIDS-associated histoplasmosis.” NCT04059770 ↗ “Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved” NCT06449040 ↗ “Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo” NCT00263315 ↗ “1. Liposomal Amphotericin B 10mg/kg IV given once” NCT06666322 ↗ “intravenous liposomal amphotericin B (10mg/kg)” NCT07261150 ↗ Show 17 more sources
Known as	MAT2203	“MAT2203” NCT03187691 ↗
Known as	Oral Encochleated Amphotericin B	“Oral Encochleated Amphotericin B (CAMB)” NCT03167957 ↗
Action	Inhibit	“This causes impairing membrane barrier function. In addition, it also causes growth inhibition.” NCT03814343 ↗
Route	Intravenous	“amphotericin B intravenously (in the vein)” NCT00000639 ↗